Bio Platforms
EXOSOMES – The Next Evolution in Therapy Delivery Beyond the Cell Membrane: The Promise of Exosomes
Linda Marbán, PhD, says perhaps the best way to get past the cell membrane is to deliver contents the same way that cells send information to each other. And that is by the exosome, which in the case of targeted therapy delivery, has been identified as an alternative that shows powerful promise.
GATC Health & Liquid Biosciences: Faster, Cheaper, More Effective Drug Discovery
Ian Jenkins, Director of Science, and Jeff Moses, CMO at GATC Health, discuss the combined benefits of their MAT platform and Liquid Biosciences’ Emerge mathematical evolution platform to help identify the right biology sooner and focus on a smaller set of potential compounds early in the pre-clinical development process to enable pharma companies to develop drugs with more efficiency and a higher success rate.
GALECTIN INHIBITORS – Is a Galectin-3 Inhibitor the Answer for Millions of Patients With Cirrhosis & Cancer?
Pol F. Boudes, MD, explains how development of a galectin-3 inhibitor could play a significant role in treating liver diseases, such as non-alcoholic steatohepatitis (NASH) and its complication, liver cirrhosis.
BIOMARKERS – Biomarkers: The Guiding Light for R&D in Heterogeneous Diseases
Thomas Turi, PhD, says while biomarkers have been a long-standing part of R&D and a mainstay of clinical practice for the characterization and diagnosis of disease for decades, they are increasingly playing a crucial role in guiding decisions to improve efficacy and efficiency of clinical trials.
2022 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
APTAMER TECHNOLOGY – From Postal Codes to GPS: Building Better Drug Conjugates With Aptamers
David Bunka, PhD, and Emily Robinson, PhD, focus on a new breed of affinity binders that can be used as an alternative to antibody therapeutics and has the potential to reshape the industry, delivering new medicines with improved safety and efficacy profiles and reduced healthcare costs.
TARGETED ONCOLOGY THERAPIES – Harnessing Nature’s “Cues” to Selectively Activate the Immune System to Attack Cancer
Dan Passeri, MSc, JD, reviews a new class of synthetic biologic drugs engineered and designed to leverage the beneficial effect of IL-2 to selectively stimulate the proliferation and cytotoxic activity of disease-relevant T cells against cancer.
EXECUTIVE INTERVIEW – Emergent CDMO: Making the Impossible, Possible for Biopharma Innovators
Catherine Hanley, Vice President & Interim CDMO Business Unit Head at Emergent BioSolutions, discusses the company’s plans for current and future CDMO operations and client partnership opportunities.
ARTIFICIAL INTELLIGENCE – Attempting to Speed Up Vaccine Development to Combat the Next Pandemic
Lars Wegner, MD, in the wake of the huge impact Covid-19 has had around the world, presents a state-of-the-art mathematical modelling and algorithms approach to vaccine development to prevent the next pandemic.
GENE THERAPY – Solving the Puzzle: Aligning the Pieces of Gene Therapy & Creating Success for Patients
Sue Washer, MBA, reviews the various elements that must come together in developing safe, effective, and commercially viable viral-based gene therapies.
EXCLUSIVE ONLINE CONTENT
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson’s Disease Dementia & Dementia with Lewy Bodies
Athira Pharma, Inc. recently announced patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson’s disease dementia and Dementia with Lewy bodies….
Biomea Fusion Announces First Patient Dosed
Biomea Fusion, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with….
Kura Oncology Receives FDA Authorization to Proceed With Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Kura Oncology, Inc. recently announced the US FDA has lifted the partial clinical hold on the KOMET-001 Phase 1b study of KO-539 in patients with…
F-star Announces Issuance of US Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 & LAG-3
F-star Therapeutics, Inc. recently announced the USPTO has granted a patent protecting the composition of matter of FS118, F-star’s tetravalent bispecific antibody which blocks PD-L1 and LAG-3 receptors…..
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248
Kinnate Biopharma Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for KIN-3248, a next-generation….